NAD+ IV vs Injection vs Oral: Which Delivery Works Best?

If you've decided you want to raise your NAD+, the next question the wellness industry pushes hard is how: an intravenous drip, a subcutaneous injection you do at home, or oral capsules and powders. The pitch for the pricier routes leans on a single argument — bioavailability. IV "delivers 100%," injections "bypass the gut," and oral is dismissed as "only 5–15% absorbed." That ranking is broadly real. But the more important fact, the one the marketing buries, is that higher blood NAD+ has not been shown to produce better health outcomes — so the route that wins on bioavailability does not automatically win on value. This guide compares the three honestly.

The bioavailability ranking is real — as far as it goes

Pharmacologically, the route hierarchy the clinics cite is directionally correct. An intravenous infusion places its contents straight into the bloodstream, so on paper it has the highest systemic availability. A subcutaneous injection bypasses first-pass gut and liver metabolism, so it should expose the blood to more of what's given than swallowing it. And an oral dose has to survive digestion and first-pass metabolism, which is why oral bioavailability of many compounds is a fraction of the dose. So far, so textbook.

Two things complicate that tidy picture for NAD+ specifically, though — and they matter a lot.

First, NAD+ itself is not well-behaved when infused. The single human study that actually measured an IV NAD+ infusion — a 2019 pilot tracking the plasma and urine metabolome over a 6-hour drip — found that free NAD+ was largely undetectable in the bloodstream for hours, as the body metabolized it en route ¹. So even the "100% bioavailable" route does not simply flood your blood with intact NAD+ the way the slogan implies. (It's also why infusions are run slowly: faster rates cause chest tightness, flushing, and nausea ¹.)

Second, the oral route clearly works at the biomarker level. The "oral barely absorbs" claim is overstated for NAD+ precursors. Oral NMN reliably raises blood NAD+ in a dose-dependent way in randomized trials ², and multiple human studies confirm oral NMN is absorbed and efficiently increases blood NAD+ ⁵⁶; oral nicotinamide riboside does the same in healthy older adults ³. So whatever the theoretical absorption percentage, the oral route demonstrably hits the target it's supposed to hit. We compare the precursors directly in NMN vs NR and the oral formats in sublingual NMN vs capsules.

The catch that flips the whole comparison

Here is the pivot the bioavailability sales pitch depends on you missing: raising blood NAD+ is not the same as improving an outcome. A route can be more bioavailable and still buy you nothing extra if the bottleneck isn't how much NAD+ reaches your blood.

And that's exactly what the outcome trials suggest. Nicotinamide riboside augmented the aged-muscle NAD+ metabolome without improving muscle performance ⁴. It raised NAD+ roughly 2.6-fold without improving cognition in older adults with mild cognitive impairment ⁷. A systematic review and meta-analysis found benefits on metabolic-syndrome parameters limited and inconsistent despite reliably higher NAD+ ⁸. If raising NAD+ via the well-absorbed oral route repeatedly fails to move the outcomes people care about, then choosing a more bioavailable route to raise NAD+ even higher is solving the wrong problem. More of an input that didn't deliver isn't a better deal — it's a more expensive version of the same uncertainty.

Route by route

Oral (capsules, powder, sublingual). The only route with a real human trial base showing it raises NAD+ ²³⁵⁶. Cheapest by far — roughly $20–$40 a month. Convenient, no needles, no clinic. Its weakness is theoretical bioavailability, but in practice it hits the biomarker; what it hasn't been shown to do — like every route — is reliably improve how you feel (see does NMN actually work).

Subcutaneous injection. Sold as a middle ground: more bioavailable than oral, cheaper and more convenient than an IV. The honest problem is evidence: there are no human outcome trials of injectable NAD+, and not even a human pharmacokinetic study of the subcutaneous route — so its real-world absorption and any benefit are assumptions, not findings. We lay this out in NAD+ injections: what the research shows.

Intravenous infusion. The most expensive and most marketed — $250–$1,500 a session — and the route with the least outcome evidence: one pharmacokinetic pilot, zero outcome RCTs ¹. It also carries the infusion side effects and the ordinary risks of IV access. Full pricing is in how much NAD+ IV therapy costs, and the evidence in our NAD+ IV therapy review.

So which is "best"?

If "best" means most proven to raise NAD+ for the least money and hassle, the answer is the unglamorous one: oral precursors. They have the human trial base, they cost a fraction of the alternatives, and they demonstrably raise the biomarker. The injectable and IV routes win the theoretical bioavailability argument but lose the evidence argument — neither has outcome trials, and the IV route's one human study shows NAD+ isn't even cleanly detectable in blood during the drip ¹.

If "best" means most proven to make me healthier, the honest answer is that no route clears that bar — every route raises (or claims to raise) a biomarker whose elevation hasn't been reliably tied to better outcomes ⁴⁷⁸. In that light, the practical decision isn't "which route absorbs best" but "how much do I want to spend on an unproven benefit" — which makes the cheapest, best-evidenced route the rational starting point and the four-figure infusion the hardest to justify. Work through that trade-off in is NAD+ therapy worth it.

The bottom line

The bioavailability ranking — IV and subcutaneous over oral — is real but mostly beside the point, because higher blood NAD+ has not been shown to mean better outcomes ⁴⁷⁸. Oral precursors are the only route with human trials confirming they raise NAD+ ²³, they cost the least, and they carry no needle or infusion risk; the injectable route has no human evidence at all; and the IV route — the priciest — rests on a single pharmacokinetic pilot in which NAD+ was barely detectable in blood ¹. Cost and practicality, not bioavailability, are the honest deciders here. Start with our NAD+ therapy evidence pillar, compare precursors in NMN vs NAD+, and see vetted products on our NAD+ rankings hub.